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Radiation-induced micronucleus induction in
lymphocytes identifies a high frequency of
radiosensitive cases among breast cancer patients:
a test for predisposition?
D Scott, JBP Barber, EL Levine, W Burrill and SA Roberts
Paterson Institute for Cancer Research, Christie CRC Research Centre, Manchester M20 9BX, UK
Summary Enhanced sensitivity to the chromosome-damaging effects of ionizing radiation is a feature of many cancer-predisposing
conditions. We previously showed that 42% of an unselected series of breast cancer patients and 9% of healthy control subjects showed
elevated chromosomal radiosensitivity of lymphocytes irradiated in the G2 phase of the cell cycle. We suggested that, in addition to the highly
penetrant genes BRCA1 and BRCA2, which confer a very high risk of breast cancer and are carried by about 5% of all breast cancerpatients,
there are also low-penetrance predisposing genes carried by a much higher proportion of breast cancer patients, a view supported by recent
epidemiological studies. Ideally, testing forthe presence ofthese putative genes should involve the use ofsimpler methodsthan the G2 assay,
which requires metaphase analysis of chromosome damage. Here we report on the use of a simple, rapid micronucleus assay in Go
lymphocytes exposed to high dose rate (HDR) or low dose rate y-irradiation, with delayed mitogenic stimulation. Good assay reproducibility
was obtained, particularly with the HDR protocol, which identified 31% (12 out of39) of breast cancer patients compared with 5% (2 out of42)
of healthy controls as having elevated radiation sensitivity. In the long term, such cytogenetic assays may have the potential for selecting
women for intensive screening for breast cancer.
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Structural chromosome changes can lead to the activation of
proto-oncogenes and elimination of tumour-suppressor genes and
therefore represent an important mechanism of tumorigenesis
(Heim and Meitelman, 1996). It is not surprising, therefore, that
elevated spontaneous levels of chromosome aberrations or
enhanced sensitivity to the induction ofaberrations by carcinogens
is a feature of many heritable conditions predisposing to cancer
(Heddle et al, 1983). Initially, it appeared that there was consider-
able specificity of carcinogen sensitivity among cancer-prone
syndromes (e.g. xeroderma pigmentosum cells sensitive to ultra-
violet irradiation, Fanconi anaemia cells to DNA cross-linking
agents and ataxia-telangiectasia cells to ionizing radiation),
whereas it is now apparent that chromosomal sensitivity to
ionizing radiation can be detected not only within these classic
chromosomal fragility syndromes but also in many other cancer-
prone groups (Table 1). This is probably because ionizing radia-
tion induces a wide range of DNA lesions that overlap with those
induced by other carcinogens (Ward, 1994) and because assays
have been improved to the extent that relatively small differences
in chromosomal radiosensitivity can now be detected. In addition,
there are several different mechanisms leading to chromosomal
radiosensitivity, including defects in DNA repair (Preston 1980;
Parshad et al, 1983), cell cycle checkpoint control (Little and
Nagasawa, 1985; Wang et al, 1996), differences in chromatin
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structure (Mozdarani and Bryant, 1989; Hittelman et al, 1994) and
in the premitotic elimination of potentially clastogenic damage
by apoptosis or premature cell senescence (Schwartz et al, 1995;
Wang et al, 1996; Williams et al, 1997).
Chromosomal radiosensitivity is, therefore, an important
biomarker of cancer predisposition. Using an assay for detecting
X-ray induced chromosome damage in lymphocytes in the G2
phase ofthe cell cycle we foundthatapproximately 40% (21 out of
50) of an unselected series ofbreast cancer cases showed elevated
chromosomal radiosensitivity compared with normal, healthy
controls (Scott et al, 1994). This observation has recently been
confirmedby Parshad et al (1996) who found that 6 outof 12 cases
with no family history of breast cancer and six out of seven cases
with a family history were sensitive. Although the family history
cases were not screened for mutations in the BRCAJ and BRCA2
genes, which confer a very high risk in about 5% ofbreast cancer
cases (Ford andEaston, 1996; Goldgaret al, 1996), it is relevant to
note that these genes appear to have a role in repair of DNA
double-strand breaks (Kinsier and Vogelstein, 1997), the lesions
directly involved in chromosome aberration formation (Natarajan
et al, 1990). A figure of 20% (22 out of 108) radiosensitive breast
cancer patients was reported by Lavin et al (1994) using G2 cell
cycle arrest inirradiated lymphoblastoid cell lines as the end point;
cases with a family history showed abnormal G2 arrest to a greater
extent that those without.
A small proportion ofG2-sensitive cases are likely to be carriers
(heterozygotes) of the recessively inherited disease, ataxia-
telangiectasia (A-T), who are sensitive in these assays (Sanford et
al, 1990; Lavin et al, 1992; Scott et al, 1994). A-T heterozygotes
have an increased risk ofbreast cancer ofapproximately four-fold
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Table 1 Cancer-prone conditions exhibiting chromosomal radiosensitivitya
Diagnosis References
Ataxia telangiectasia homozygotes
Ataxia telangiectasia heterozygotes
Basal cell naevus syndrome
Bloom's syndrome
Common variable immune disorder
Down's syndrome
Dyskeratosis congenita
Epidermodysplasia verruciformis
Familial dysplastic naevus syndrome
Fanconi's anaemia
Gardner's syndrome
Klinefelter syndrome
Li-Fraumeni syndrome
Nijmegen breakage syndrome
Rothmund-Thomson syndrome
Trisomy-18
Porokeratosis of mibelli
Retinoblastoma (familial)
Wilms' tumour
Xeroderma pigmentosum
Higurashi and Conen (1973); Taylor et al (1976); Sanford et al (1990)
Sanford et al (1990); Waghray et al (1990); Scott et al (1994); Jones et al (1995)
Featherstone et al (1983)
Higurashi and Conen (1973); Kuhn (1980)
Vorechovsky et al (1993)
Sasaki et al (1970); Morten et al (1991); Countryman et al (1977)
DeBauche et al (1990)
el-Zein et al (1995)
Sanford et al (1987)
Higurashi and Conen (1973); Heddle et al (1978); Parshad et al (1983);
Duckworth-Rysiecki and Taylor (1985); Gibbons et al (1995)
Parshad et al (1983)
Sasaki et al (1970)
Parshad et al (1993)
Taalman et al (1983); Taalman et al (1989); Jaspers et al (1988)
Kerr et al (1996)
Sasaki et al (1970)
Takeshita et al (1994); Watanabe et al (1990)
Morten et al (1991); Sanford et al (1996)
Sanford et al (1989)
Price et al (1991)
aTested in cells irradiated in different phases of the cell cycle. Includes metaphase and micronucleus analysis.
so the A-T gene is regarded as being ofrelatively low penetrance
and does not lead to strong family history ofbreast cancer (Easton,
1994). It is estimated that about 4% ofbreast cancer cases are A-T
gene carriers (Easton, 1994). As our G2 chromosomal radiosensi-
tivity testing gave a figure for sensitivity that was some tenfold
greater, we proposed the existence of other low penetrance genes
that predispose to breast cancer, in addition to the A-T gene (Scott
et al, 1994). Recent epidemiological studies support this view by
demonstrating that the highly penetrant predisposing genes
BRCAJ and BRCA2, cannot account for the overall increased risk
in the relatives ofbreast cancer cases in general (Teare et al, 1994;
Chen et al, 1995).
The G2 chromosomal radiosensitivity assay requires expertise in
the identification of structural chromosome changes in metaphase
cells. Ifchromosomal radiosensitivity tests are to be used in popula-
tion studies of cancer predisposition, it would be preferable to
simplify and speed up the identification ofchromosome damage. A
possible method is to quantify micronuclei in post-mitotic cells,
a task that can be performed easily and rapidly by relatively
inexperienced observers (Fenech and Morley, 1985) and has the
potential forautomation (Verhaegen et al, 1994; Bockeret al, 1995).
We have been unable to convert the G2 metaphase method into a
micronucleus assay because too few metaphase chromosome frag-
ments lead to micronuclei. However, we have obtained reasonable
discrimination between normal and A-T heterozygotes by
measuring micronucleus induction in lymphocytes exposed to low
dose rate (LDR) y-irradiation in the Go phase of the cell cycle
(Scott etal, 1996). The use ofLDR exposure is believed to amplify
small differences in repair capacity (Jones et al, 1995). An alterna-
tive method of amplification is by delaying mitogenic stimulation
of irradiated Go cells to allow time for the expression of differen-
tial repair (Little and Nagawawa, 1985). Delaying stimulation for
a few hours results in a reduction of chromosome damage in
lymphocytes, presumably reflecting repair of lesions that lead to
aberrations (Jones, 1995).
In the present study, we have compared sensitivity to radiation-
induced micronucleus (MN) induction of healthy controls with
that of an unselected series of women with breast cancer.
Lymphocytes were exposed to high or low dose rate irradiation in
Go and mitogen stimulated 6 h later. In a study to assess the repro-
ducibility of the assay, we performed six repeat experiments on
each offive healthy controls.
MATERIALS AND METHODS
Selection of controls
The controls were selected from normal volunteers including some
spouses of the breast cancer patients. In the study of assay repro-
ducibility, we performed a series ofexperiments on a panel offive
control individuals who agreed to give blood samples on six
occasions over a period of 6 months. The five control subjects
comprised two men and three women andranged in age from 23 to
46 years. These individuals are hereafter referred to as 'controls'.
A further 42 normal volunteers were each tested on a single occa-
sion and are subsequently referred to as 'normals'. Nineteen ofthe
normals were tested in a planned series in which one of the five
controls, one or two normals and one or two cancer patients were
tested in parallel in each experiment (series A). A further series
(series B) of 23 normals was also tested and as there were no
differences inresults between the two series they have been pooled
for analysis. Normals comprised 28 women and 14 men between
23 and 72 years ofage.
Selection of breast cancer cases
The breast cancer cases were all attending the Christie Hospital for
post-operative radiotherapy after a wide local excision with breast
conservation 8-12 weeks earlier. They were either stage TI
(n = 27) or T2 (n = 12) and were all node negative apart from six
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Figure 1 Micronucleus (0) and binucleate cell (C1) frequencies in
lymphocytes of a normal donor exposed to 3.5 Gy HDR irradiation and
harvested between 68 and 94 h after PHA stimulation
patients, who were stage NI (UICC TNM stage). They ranged
in age from 35 years to 70 years. None had any evidence of
metastatic disease or had any exposure to cytotoxic chemotherapy.
Blood samples were taken for the micronucleus assay before
radiotherapy commenced as localized radiotherapy may affect the
in vitro radiosensitivity oflymphocytes (Rigaud et al, 1990). Their
age, grade of tumour, menopausal status, tamoxifen intake,
smoking history and family history ofbreast cancer were recorded.
Micronucleus assay
The protocol was basically that ofFenech and Morley (1985) with
optimization of conditions based upon our previous experience of
Go chromosomal radiosensitivity assays (e.g. Jones, 1995; Jones et
al, 1995; Scott et al, 1996).
Blood samples were obtained (with consent and ethical approval)
by venepuncture, using sodium heparin as an anticoagulant. The
blood was always stored overnight at room temperature and then
diluted 1:10 with tissue culture medium (RPMI-1640, 20% fetal
calf serum and 4 mM L-glutamine) prewarmed to 37°C in a 5%
carbon dioxide atmosphere. The same serum batch was used
throughout the investigations. Forthe HDR assay, two 5-ml aliquots
ofthe blood in medium were placed in tissue culture flasks (Falcon
T25). Theflasks were kept for 1 h at 37°C before one flask was irra-
diated with 3.5 Gy '37Cs y-rays (dose rate 1.0 Gy min-') and the
other sham irradiated. For the LDR assay, samples were divided
between two tissue culture 24-well plates (Falcon), 2 ml per well,
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Figure 2 Micronucleus frequencies in five normal donors each tested six
times for sensitivity to HDR (U) or LDR (El) irradiation (3.5 Gy). Dashed lines
indicate the mean values of the six repeat tests
two wells per sample, one plate to be irradiated with 3.5 Gy '37Cs
,y-rays (dose rate 0.15 cGy min-1, total exposure time 38.8 h) and the
other to act as a sham-irradiated control. Throughout the irradiation
period, all samples were maintained at 37°C in 5% carbon dioxide
atmosphere in apurpose-built irradiation facility.
After irradiation, the protocol was the same for both assays.
After a period of 6 h the lymphocytes were stimulated with the
mitogen phytohaemagglutinin (PHA; Murex, HAl5, final concen-
tration 10 jig ml-'). Twenty-four hours after stimulation, the
cytokinesis-blocking agent cytochalasin-B (Sigma chemicals) was
added to the cultures at a final concentration of 6 jg ml'. First
generation post-mitotic cells could subsequently be identified as
binucleated cells (Fenech and Morley, 1985). In a preliminary
experiment we investigated the effect of harvesting time on MN
yields because of previous conflicting reports (Lee et al, 1994;
Kligerman and King, 1995). We found a steep increase in MN
frequencies between 68 and 76 h and a plateau level thereafter
(Figure 1). We therefore chose a 90 h sampling time for these
studies, which has the additional advantage of a higher yield of
binucleate cells for MN analysis than the usual sampling time of
72 h (Figure 1).
Table 2 Radiation-induced micronucleus yields in normal and breast cancer patients (Figures 3 and 4)
Micronuclel per 100 cells ± s.d.
Group Dose rate Men Women All cases
Normal HDR 44.6 ± 7.0 46.4 ± 9.8 45.8 ± 8.9
(n = 42) (n = 14) (n = 28)
LDR 23.1 ± 3.6 20.8 ± 5.9 22.2 ± 5.3
Breast cancer cases (n = 39) HDR - 60.7 ± 9.6 60.7 ± 9.6a
LDR - 26.4 ± 7.9 26.4 ± 7.9a
aSignificant difference (Mann-Whitney U-test) between normal subjects and breast cancer patients; high dose rate (HDR),
P< 0.001; low dose rate (LDR), P = 0.003.
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For harvesting, the cultures were centrifuged at 1000 r.p.m. for
5 min, the supernatant aspirated and the cells resuspended in
0.075 M potassium chloride at 4°C to lyse the erythrocytes. After
exactly 2 min, the cells were centrifuged (1000 r.p.m. for 5 min),
the supernatant rapidly aspirated and the cell pellet resuspended
in approximately 0.5 ml of remaining solution. To this was added
5 ml of fixative (methanol-acetic acid, 25:1). All harvesting
procedures and reagents were at ambient temperature unless other-
wise stated. After further centrifuging and changing the fixative,
they were stored at 4°C overnight. The samples were allowed to
reach ambient temperature, centrifuged and most of the super-
natant discarded. The cells were resuspended in approximately
0.5 ml of the remaining fixative, dropped gently onto slides and
air-dried before staining (Leishman's full strength for 3 min, 30%
stain for 12 min, diluted with buffer at pH 6.8), washing three
times with pH 6.8 buffer, and drying and mounting.
All slides were coded, randomized to ensure anonymity of
samples and analysed by one observer at a magnification ofx 500,
using a x 25 oil immersion objective. For series A the proportion
ofmono-, bi- and polynucleated cells was recorded in 100 consec-
utive cells, and for series A and B the micronucleus frequency was
recorded in 100 consecutive binucleate cells. The criteria for
scoring micronuclei were broadly similar to those ofCountryman
and Heddle (1976). To calculate the radiation induced micro-
nucleus frequency per 100binucleate cells (hereafter designated as
the induced MN yield), the spontaneous micronucleus frequency
in the unirradiated sample was subtracted from that obtained for
the irradiated sample.
Statistical analysis
A one-way analysis ofvariance was used to quantify the inter- and
intraindividual variance within the assay.
Groups were compared using non-parametric Mann-Whitney
U-tests and Kruskall-Wallis tests. Correlations between contin-
uous variables (e.g. MN yields and age) were tested using
Spearman's Rank correlation tests, and it is this correlation coeffi-
cient that is quoted here.
The numbers of sensitive patients were determined by selecting
an arbitrary cut-off of the mean + 2 s.d. of the normal population
(this would be an approximate 95% confidence limit ifthe popula-
tion were large and the values normally distributed).
RESULTS
Assay reproducibility
The five normal controls were each tested six times. The mean
induced MN scores were 44.0 ± 4.8 at HDR and 19.2 ± 3.6 at
LDR. The coefficient ofvariation within individuals, calculated by
one-way analysis of variance was 9% at HDR and 18% at LDR,
indicating good assay reproducibility (Figure 2) particularly at
HDR, such that there were significant interindividual differences
at HDR (P = 0.006) but not at LDR (P = 0.36).
Comparison of breast cancer cases with normals
The breast cancer cases (n = 39) were significantly more radiosen-
sitive than the normals (n = 42) at HDR (P < 0.001). At LDR the
difference was smaller but statistically significant (P = 0.003).
Results are presented in Table 2 and Figures 3 and 4. The propor-
tion ofbreast cancer cases with HDR MN yields that were greater
than the mean + 2 s.d. ofthe normals was 31% (12 out of39). The
corresponding figure for normals was 5% (two out of 42),
compared with an expectation of 2.5% for a normally distributed
population. This 'cut-off' point is shown in Figure 3. At LDR,
15% (six out of 39) ofthe cancer patients and 5% (2 out of42) of
the normals were sensitive using the mean + 2 s.d. cut-off. There
was only a weak correlation between HRD and LDR responses in
patients [r = (correlation coefficient) 0.18, P = 0.29] and normals
(r = 0.33, P = 0.04). In part, this may be due to the experimental
variability of the LDR assay but may also indicate that the HDR
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Figure 3 Micronucleus frequencies in normal subjects and breast cancer
patients after HDR irradiation. Dashed lines represent mean values. The
solid line indicates the 'cut-off' point for sensitivity, i.e. mean of normal +
two s.d.s
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Figure 4 Micronucleus frequencies in normal subjects and breast cancer
patients after LDR irradiation. See legend to Figure 3 for further details
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Figure 5 Relationships between induced MN yields (HDR) and age for
normal subjects and breast cancer patients. Dashed and dotted regression
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and LDR assays are detecting different mechanisms of chromo-
somal radiosensitivity.
Spontaneous MN yields in breast cancer cases (1.6 ± 1.2; 200
cells scored from each of 39 cases) were significantly higher than
in normals (0.7 ± 0.9; 200 cells from 42 individuals), P = 0.001 in
a Mann-Whitney U-test.
Potential confounding factors
There was a significant difference between the average age of the
breast cancer patients (58.5 ± 7.4) and the normal subjects
(47.8 ± 13.4, P < 0.001), and because ofthis there appears to be an
increase in induced MN with age after HDR exposure when data
for patients and normal subjects are combined (HDR, r = 0.30, P =
0.007, LDR, r = 0.11, P = 0.33). However, there was no age effect
for cancer patients (HDR, r = 0.05, P = 0.75, LDR, r = 0.04, P =
0.81) or normals (HDR, r = -0.06, P = 0.71, LDR, r = -0.09, P =
0.57) when analysed separately (Figure 5), which suggests that the
differences observed between breast cancer patients and normal
subjects is not due to an age bias.
Among the normals there was no significant difference in
response between men and women (Table 2), although the distrib-
ution ofthe sexes was biased towards women (n = 28, men n = 14).
Within the breast cancer group there was no significant correla-
tion between induced MN scores (at HDR or LDR) and stage or
grade of tumour, tamoxifen intake, menopausal status or smoking
history.
Only three patients had any blood relatives with breast cancer.
Each had one affected first degree relative. The three tested
patients had HDR MN yields of 61, 52 and 91, respectively, with
the last being the most sensitive of the 39 patients tested and the
other two being well within the normal range for breast cancer
cases (Fig. 3) and below the cut-offpoint for normal donors.
Cell proliferation
At the 90 h harvesting time approximately 60% ofcells were binu-
cleate and 75% were either bi- or polynucleate (having undergone
one or more mitotic divisions since stimulation), regardless of
whether the samples were from normals or breast cancer patients
or whether or not they were irradiated (Table 3). In our previous
Table 3 Cell proliferation indices in normal and breast cancer patients
Post-mitotic cells ± s.d. (%)
Group Dose rate Binucleate Bi- + polynucleate
Normal subjects HDR 61.1 ± 6.6 73.3 ± 6.3
(n = 19a) HDR controlb 60.8 ± 8.6 72.6 ± 7.7
LDR 66.0 ± 7.7 75.5 ± 6.5
LDR controlb 63.9 ± 16.1 74.5 ± 17.4
Breast cancer HDR 59.7 ± 6.7 72.3 ± 6.5
cases (n = 39) HDR controlb 63.6 ± 7.9 75.4 ± 6.7
LDR 64.8±8.1 74.5±7.8
LDR controlb 64.7 ± 6.3 76.3 ± 6.4
aCell proliferation was studied only in series A. bUnirradiated control samples
were run in parallel with both the HDR and LDR samples.
study using a 72 h sampling time (Scott et al, 1996), the corre-
sponding figures for normals were approximately 45% and 50%,
respectively, for unirradiated samples and significantly less after
irradiation, probably indicating mitotic delay. The use of a later
sampling time has the advantage of a greater yield of binucleate
cells for MN analysis, and by 90 h the cells appear to have
recovered from mitotic delay.
DISCUSSION
Our use of LDR irradiation in these studies was based upon our
previous observation that, in Go lymphocytes, discrimination
between the chromosomal radiosensitivity of normals and A-T
heterozygotes was possible only at LDR and not at HDR (Jones et
al, 1995; Scott et al, 1996). However, in the previous studies PHA
stimulation of HDR-irradiated lymphocytes occurred shortly after
irradiation, whereas here we have allowed a 6-h interval for repair.
It is likely that this modification ofthe HDR protocol, and the fact
that there is less experimental variability at HDR than at LDR, has
resulted in a better discrimination between normals and breast
cancer cases at HDR. Indeed, we have now been able to discrimi-
nate between normals and A-T heterozygotes using this HDR
protocol (unpublished observations). However, the rather weak
correlation between HDR and LDR responses that we have seen in
the present study suggests that these assays may be detecting
different mechanisms of chromosomal radiosensitivity, and that
some breast cancer cases and normals are defective in the 'HDR
mechanism' and not in the 'LDR mechanism' and vice versa. We
are further investigating this question in studies oflarger numbers
ofindividuals.
The proportion of breast cancer cases that were sensitive in the
HDR assay (31%) is similar to that found with our G2 method
(42%, Scott et al, 1994). However, the exact proportion of sensi-
tive cases is very dependent on the level of cut-off used. The
present choice of the mean + 2 s.d. of normals is arbitrary but
reasonable. Larger studies are required to more accurately define
this threshold. We are now investigating the correlation between
GJ/MN and G2 sensitivity in the same individuals. Already, from
preliminary studies, it is evident that there are patients who are G2
sensitive but notGo/MN sensitive and vice versa.
As described earlier, there are clearly several different mecha-
nisms underlying elevated chromosomal radiosensitivity. Even
within breast cancer cases there may be three pathways detected
British Journal ofCancer (1998) 77(4), 614-620
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by different assays (G2, HDRIMN, LDR/MN). If enhanced
chromosomal radiosensitivity is indeed indicative of cancer
predisposition, it follows that no single assay will detect all 'at-
risk' individuals. Our results to date suggest that the proportion of
breast cancer patients sensitive in one or more of our three assays
will considerably exceed 50%. This figure is not inconsistent with
recent epidemiological studies suggesting genetic predisposition,
via low-penetrance genes, in a high proportion of breast cancer
cases (Teare et al, 1994; Chen et al, 1995; Houlston et al, 1996).
Many further studies will be required before chromosomal
radiosensitivity assays could confidently be used to predict cancer
predisposition in the general population. For example, it has to be
shown that elevated chromosomal radiosensitivity is a heritable
trait (family studies), that it is specific for cancer (studies of
diseases otherthan cancer, both heritable and non-heritable), that it
is not a consequence of physical and psychological stresses
associated with diagnosis or treatment (follow-up studies after
treatment) and that it correlates with the degree of genetic predis-
position (studies of common cancers other than breast). We are
investigating all ofthese possibilities. Ultimately, it mustbe shown
that healthy individuals with elevated sensitivity are at greater risk
of cancer than those of normal sensitivity (prospective studies).
Knight et al (1993) have indirectly addressed this last question
using the G2 assay and have demonstrated a stronger family history
of cancer in chromosomally radiosensitive cases, which is an
encouraging observation.
The ability to identify individuals within the general population
at increased risk of common cancers could lead to more effective
use of resources in targeting individuals for intensive screening.
Cytogenetic assays ofradiosensitivity may have an important role
in selecting these individuals.
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